Although MerTK-targeting in experimental MASH models has demonstrated to reduce liver fibrosis, MerTK was also shown to confer hepatocyte protection against lipotoxicity through Gas6. Here, GAS6 is linked to metabolic dysfunction-associated steatohepatitis.